Moneycontrol PRO
you are here: HomeNewsWorld

EU okays new J&J COVID vaccine production site

In a statement Friday, the EU drug regulator said the new site in Anagni, Italy, will finish manufacturing of the J&J vaccine, which was licensed for use in adults across Europe in March.

June 26, 2021 / 08:19 AM IST
In a statement, China's Foreign Ministry said it did not see a link between the recent COVID-19 outbreaks and its vaccines. (Representative image)

In a statement, China's Foreign Ministry said it did not see a link between the recent COVID-19 outbreaks and its vaccines. (Representative image)

The European Medicines Agency has approved a new manufacturing site for Johnson & Johnson''s COVID-19 vaccine, in a move that should boost production of the one-dose vaccine across the 27-nation EU.

In a statement Friday, the EU drug regulator said the new site in Anagni, Italy, will finish manufacturing of the J&J vaccine, which was licensed for use in adults across Europe in March.

Production problems have stalled J&J''s roll-out across the European Union in recent months and millions of doses made at a U.S. factory had to be thrown out after contamination issues.

The EU has ordered 200 million doses of the J&J vaccine and was expecting 55 million by the end of June; to date, fewer than 14 million doses have been distributed.

J&J''s vaccine roll-out was also stalled after the EMA concluded there was a “possible link” between the coronavirus shot and very rare blood clots and recommended that a warning should be added to the label. Health officials say the vaccine''s benefits still far outweigh the risks.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
PTI
first published: Jun 26, 2021 08:19 am